Tirzepatide: what real-world users report

A survey published in Obesity Pillars in September 2026 asked a simple question about once-weekly tirzepatide: once people are actually living with the drug, what do they and their doctors make of it? Across 151 United States prescribing physicians and 199 patients with obesity or overweight but without type-2 diabetes, more than 90% of the patients asked said they would recommend it to someone in their position, and 78.5% of physicians reported treatment success in their patient populations^[1].

What the survey actually measured

This was a cross-sectional survey, not a clinical trial. The researchers, led by Theresa Hunter Gibble and colleagues, collected two waves of United States responses, one from October 2023 to April 2024 and a second from October 2024 to January 2025^[1]. Physicians reported on the patients they treat, and patients reported on their own experience. The patient group was drawn to reflect people using tirzepatide for weight rather than diabetes, so the findings speak to the obesity indication specifically.

These were not otherwise-healthy volunteers. 84.4% of the patients carried at least one obesity-related complication, most often hypertension and dyslipidemia (abnormal blood fats)^[1]. That context matters when you read the satisfaction numbers. These are people managing real metabolic disease, not a cosmetic weight-loss crowd, and their standard for whether a drug is worth staying on is a demanding one.

What patients and physicians reported

On the headline measure, patient enthusiasm was high. Of the 48 patients asked directly about recommending tirzepatide, more than 90% (45 of them) said they were likely to do so^[1]. Physicians pointed to a consistent set of reasons for reaching for it in the first place: they cited long-term safety, ease of dosing, and reduced appetite as the main drivers^[1]. The once-weekly injection schedule and the appetite effect track with what the trial programme has reported for the molecule.

The efficacy backdrop is not in dispute. In SURMOUNT-1, the pivotal randomised trial of 2,539 adults with obesity, the 15 mg weekly dose produced a mean body-weight reduction of 20.9% at 72 weeks against 3.1% on placebo^[3]. A survey like this one does not add to that evidence base. What it adds is the human texture around the numbers: whether people stay motivated, whether the regimen fits a life, and whether they would choose it again. That is the gap trials rarely fill, because a drug can perform inside a protocol and still fail outside one.

Why satisfaction is not the same as proof

Read the figures for what they are. Satisfaction and likelihood-to-recommend are self-reported attitudes, gathered at a single point in time, with no control group and no blinding. People who abandoned tirzepatide because they could not tolerate it, or could not afford it, are underrepresented in a sample of current users. The subgroup asked about recommending the drug was small, just 48 people, so a figure above 90% rests on a handful of responses. Several of the authors are affiliated with the manufacturer, which is disclosed but worth holding in mind.

None of that makes the findings worthless. Real-world satisfaction data fills a genuine gap, and adherence is one of the biggest predictors of whether an obesity medicine works over years rather than months. But satisfaction measures experience, not safety or long-term outcome. The tolerability story is well documented elsewhere: gastrointestinal effects (nausea, diarrhoea, vomiting and constipation) are the most common adverse reactions on the tirzepatide label and the most common reason people stop^[4]. A survey of people still taking the drug is, by design, not the place to read that signal.

Where this lands

Tirzepatide is a prescription-only medicine everywhere PeptideMethods covers. In the European Union it is centrally authorised by the EMA as Mounjaro for both type-2 diabetes and weight management, with Eli Lilly Nederland as the marketing authorisation holder^[2]. The United States label carries a boxed warning about thyroid C-cell tumours seen in rats, and a personal or family history of medullary thyroid carcinoma is a contraindication^[4]. A high satisfaction score changes none of that.

If you are weighing tirzepatide, this survey is a data point about how other people found the experience, not a substitute for the conversation with a clinician about whether it fits your history. The full regulation and safety detail sits on the tirzepatide page, and if you are comparing options, the head-to-head evidence against semaglutide is a more useful place to start than any recommendation score.